Biomanufacturing strategy at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
35 organizations at BIO-Europe 2026 present work in biomanufacturing strategy: 22 drug developers, 8 service providers, 3 academic, government and non-profit bodies and 2 investors. Between them they bring 59 presentations to the program. Most represented: Bayer (7 on the program), Boehringer Ingelheim (4 on the program), Johnson & Johnson (4 on the program). 15 of them have their own page in this guide. As of Sep 29, 2026.
Format
Top represented
Showing 1–12 of 35 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Bayer Leverkusen, Germany | ◆Platinum Sponsor |
Life sciences company with pharmaceuticals, consumer health and crop science divisions. | Talk Tue Nov 10 09:00–09:30 An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. Business of BiotechBiomanufacturing Strategy Panel Tue Nov 10 16:30–16:55 The Role of Innovation in Biopharma Growth How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. Panel Wed Nov 11 09:00–10:00 Collaborative Innovation in CDMO Partnerships How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle. |
Boehringer Ingelheim Ingelheim am Rhein, Germany | ◆Platinum Sponsor |
Family-owned pharmaceutical company developing human and animal health medicines. | Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Johnson & Johnson New Brunswick, NJ | ◇Silver Sponsor |
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Tue Nov 10 10:00–10:25 Regulatory Updates for Orphan and Paediatric Medicines How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. Panel Wed Nov 11 13:00–13:45 What's Next for Biomanufacturing Strategies? Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up. |
Novo Nordisk Bagsværd, Denmark | ◆Gold Sponsor |
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases. | Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 15:30–15:55 Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. Panel Wed Nov 11 11:00–11:30 Sustainability & Innovation: Transforming Biopharma Partnerships for a Greener Future How drug companies, smaller firms and suppliers can team up to cut supply chain carbon emissions and bring greener technologies to industrial scale. |
Miltenyi Biomedicine Bergisch Gladbach, Germany | |
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies What changes when cell therapies first developed for cancer move into autoimmune disease, from acceptable safety risks and trial endpoints to manufacturing. |
Evotec Hamburg, Germany | ◆Platinum Sponsor |
Drug discovery and development partner providing research services and biologics development and manufacturing to pharma and biotech. | Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. Business of BiotechBiomanufacturing Strategy Panel Wed Nov 11 09:00–10:00 Collaborative Innovation in CDMO Partnerships How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle. |
Lonza Basel, Switzerland | ◆Platinum Sponsor |
Contract development and manufacturing organization for biologics, small molecules, and cell and gene therapies. | Panel Mon Nov 9 15:30–15:55 Beyond the Race to IND: Balancing Speed, Risk and Future Value When racing to first human trials pays off for a biotech, and when that speed creates risks for manufacturing and growth later on. Panel Tue Nov 10 15:00–15:25 Scaling Biologics Manufacturing in a Changing World: How Biopharma is Rethinking Launches, Partnerships and Resilience How political uncertainty and trade shifts are changing how drug companies pick outside manufacturers, including whether to produce closer to home. |
Pfizer New York, NY | ◇Silver Sponsor |
Pharmaceutical company developing and marketing medicines and vaccines across oncology, vaccines, internal medicine and other areas. | Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. Keynote Tue Nov 10 13:00–13:45 Keynote: Day in the Life of an experienced dealmaker Experienced drug-company dealmakers and venture investors share how they see the life sciences industry today and how biotechs can find their way. |
Lundbeck Copenhagen, Denmark | |
Danish pharmaceutical company focused on brain diseases, including psychiatry, neurology and migraine. | Panel Tue Nov 10 15:00–15:25 Scaling Biologics Manufacturing in a Changing World: How Biopharma is Rethinking Launches, Partnerships and Resilience How political uncertainty and trade shifts are changing how drug companies pick outside manufacturers, including whether to produce closer to home. Panel Wed Nov 11 13:00–13:45 HTA Regulation: Early Insights and Reimbursement Implications Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access. |
UCB Brussels, Belgium | |
Biopharmaceutical company developing and marketing medicines for immunology and neurology. | Panel Tue Nov 10 14:30–14:55 Intellectual Property Strategy in Early-Stage Biomanufacturing: Building Competitive Advantage from Day One Whether young companies should patent a new manufacturing process or keep it secret, and how to show partners their intellectual property holds up. Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
AV Angelini Ventures Rome, Italy | |
Corporate venture capital arm of Angelini Industries, investing in biotech, medtech and digital health companies. | Keynote Mon Nov 9 12:00–12:45 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition and CEOs How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. Business of BiotechBiomanufacturing Strategy |
Instantly find 20 buyers in biomanufacturing strategy
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
- Business of Biotech 68
- Ecosystem Innovation 71
- Therapeutic Insights 52
- Biomanufacturing Strategy 35
- Clinical Strategy 30
- Regulatory Strategy 30
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction